Skip to main content

Table 2 Demographic characteristics in the total vaccinated cohort

From: Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial

  AS03C AS03C-MPL25 AS03C-MPL50 AS03B AS03B-MPL25 AS03B-MPL50 AS03A AS03A-MPL25 Non-adjuvanted ≥65 years Non-adjuvanted 18–40 years
  N=204 N=202 N=198 N=202 N=199 N=199 N=202 N=198 N=200 N=203
Age at vaccination (years)
 Mean±SD 72.7±5.75 72.9±6.09 72.6±5.67 72.6±5.16 72.5±5.66 73.0±6.03 72.4±5.62 72.7±5.56 72.7±5.43 27.4±6.25
 Median (min–max) 72.0 71.0 72.0 72.0 72.0 72.0 71.0 72.0 72.0 27.0
(63–91) (64–91) (65–94) (65–87) (65–91) (62–95) (65–90) (65–88) (65–89) (18–40)
Gender, n (%)
 Female 95 (46.6) 100 (49.5) 96 (48.5) 109 (54.0) 89 (44.7) 95 (47.7) 105 (52.0) 102 (51.5) 90 (45.0) 103 (50.7)
 Male 109 (54.3) 102 (50.5) 102 (51.5) 93 (46.0) 110 (55.3) 104 (52.3) 97 (48.0) 96 (48.5) 110 (55.0) 100 (49.3)
Geographic Ancestry, n (%)
 African/African American 1 (0.5) 0 2 (1.0) 0 0 1 (0.5) 0 1 (0.5) 0 2 (1.0)
 Asian–Central/South 1 (0.5) 0 0 0 0 0 0 0 0 0
 Asian–South East 1 (0.5) 1 (0.5) 2 (1.0) 0 0 1 (0.5) 2 (1.0) 0 0 0
 White–Arabic/North African 2 (1.0) 1 (0.5) 1 (0.5) 1 (0.5) 1 (0.5) 1 (0.5) 0 3 (1.5) 0 2 (1.0)
 White–Caucasian/European 199 (97.5) 199 (98.5) 193 (97.5) 201 (99.5) 197 (99.0) 195 (98.0) 198 (98.0) 194 (98.0) 200 (100.0) 197 (97.0)
 Other 0 1 (0.5) 0 0 1 (0.5) 1 (0.5) 2 (1.0) 0 0 2 (1.0)
  1. TVC, total vaccinated cohort; All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).